Management of Primary Aldosteronism

Displaying 1 - 6 of 6CSV
Satheesh, G., Dhurjati, R., Jha, V., Schutte, A. E., Banigbe, B., Prabhakaran, D., Moran, A. E., & Salam, A. (2024). Effectiveness and Safety of Using Standardized Treatment Protocols for Hypertension Compared to Usual Care: A Meta‐Analysis of Randomized Clinical Trials. The Journal of Clinical Hypertension. Portico. https://doi.org/10.1111/jch.14950
Publication Date
McLennan, G., Quencer, K., Dolmatch, B., Kennedy, R., McClure, T., Vingan, H., Arslan, B., Werder, G., Krishnasamy, V., Le, T., Meisinger, Q., Muller, R., Field, D., Haddad, M., Kumari, D., Kulkarni, S., Nguyen, Q., Achakzai, B., Sharma, P., … Penninga Brown, E. (2024). Abstract No. 292 Distribution of Interventional Radiology Expertise with Management of Primary Aldosteronism–Related Hypertension. Journal of Vascular and Interventional Radiology, 35(3), S129. https://doi.org/10.1016/j.jvir.2023.12.333
Publication Date
Wood, M. E., Xiong, L. Y., Wong, Y. Y., Buckley, R. F., Swardfager, W., Masellis, M., Lim, A. S. P., Nichols, E., Joie, R. L., Casaletto, K. B., Kumar, R. G., Dams‐O’Connor, K., Palta, P., George, K. M., Satizabal, C. L., Barnes, L. L., Schneider, J. A., Binet, A. P., … Villeneuve, S. (2023). Sex differences in associations between APOE ε2 and longitudinal cognitive decline. Alzheimer’s & Dementia, 19(10), 4651–4661. Portico. https://doi.org/10.1002/alz.13036
Publication Date
Derington, C. G., Bress, A. P., Berchie, R. O., Herrick, J. S., Shen, J., Ying, J., Greene, T., Tajeu, G. S., Sakhuja, S., Ruiz-Negrón, N., Zhang, Y., Howard, G., Levitan, E. B., Muntner, P., Safford, M. M., Whelton, P. K., Weintraub, W. S., Moran, A. E., & Bellows, B. K. (2023). Estimated Population Health Benefits of Intensive Systolic Blood Pressure Treatment Among SPRINT-Eligible US Adults. American Journal of Hypertension, 36(9), 498–508. https://doi.org/10.1093/ajh/hpad047
Publication Date
Douxfils, J., Gaspard, U., Taziaux, M., Jost, M., Bouvy, C., Lobo, R. A., Utian, W. H., & Foidart, J.-M. (2022). Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric, 26(1), 55–63. https://doi.org/10.1080/13697137.2022.2139599
Publication Date
Zeni, C., Dedic, N., Jones, P., Wu, S., Anacker, C., Hajos-Korcsok, E., Synan, C., Milanovic, S., Hopkins, S., Bristow, L., & Koblan, K. (2022). Ulotaront improves metabolic parameters in rodent models of weight gain and hyperglycemia. Neuroscience Applied, 1, 100356. https://doi.org/10.1016/j.nsa.2022.100356
Publication Date